Study details
Enrolling now
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Ascendis Pharma A/S
NCT IDNCT06079398ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
72
Study length
about 3.2 years
Ages
0–2
Locations
3 sites in MN, TX, WI
What this study is about
This trial is testing a treatment called Navepegritide, which is given by injection under the skin once a week for 52 weeks. The goal is to see if this treatment helps infants with achondroplasia grow taller and is safe.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Navepegritide
- 2.Take Placebo for Navepegritide
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: To evaluate the safety and tolerability of Navepegritide